Healius Ltd

AU:HLS Australia Diagnostics & Research
Market Cap
$265.27 Million
AU$428.42 Million AUD
Market Cap Rank
#14816 Global
#196 in Australia
Share Price
AU$0.59
Change (1 day)
+2.61%
52-Week Range
AU$0.58 - AU$1.60
All Time High
AU$4.91
About

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patie… Read more

Healius Ltd - Asset Resilience Ratio

Latest as of December 2015: 0.06%

Healius Ltd (HLS) has an Asset Resilience Ratio of 0.06% as of December 2015. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
AU$2.43 Million
Cash + Short-term Investments
Total Assets
AU$3.91 Billion
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (2002–2017)

This chart shows how Healius Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Healius Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$2.43 Million 0.06%
Total Liquid Assets AU$2.43 Million 0.06%

Asset Resilience Insights

  • Limited Liquidity: Healius Ltd maintains only 0.06% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Healius Ltd Industry Peers by Asset Resilience Ratio

Compare Healius Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ADCNF
OTCGREY:ADCNF
Diagnostics & Research 1.12%
Berry Genomics Co Ltd
SHE:000710
Diagnostics & Research 0.45%
NSN Co. Ltd
KQ:031860
Diagnostics & Research 1.72%
JOONGANG DNM Co.Ltd
KQ:051980
Diagnostics & Research 27.26%
GeneMatrix Inc
KQ:109820
Diagnostics & Research 41.52%
Genoray Co. Ltd
KQ:122310
Diagnostics & Research 0.03%
Green Cross Lab Cell Corporation
KQ:144510
Diagnostics & Research 0.18%
Optipharm.CO.LTD
KQ:153710
Diagnostics & Research 20.73%

Annual Asset Resilience Ratio for Healius Ltd (2002–2017)

The table below shows the annual Asset Resilience Ratio data for Healius Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2017-06-30 0.00% AU$0.00 AU$3.11 Billion --
2016-06-30 0.00% AU$0.00 AU$3.62 Billion --
2015-06-30 0.08% AU$3.20 Million AU$3.92 Billion -0.04pp
2012-06-30 0.12% AU$4.57 Million AU$3.86 Billion +0.10pp
2011-06-30 0.02% AU$798.00K AU$3.83 Billion -0.02pp
2010-06-30 0.04% AU$1.50 Million AU$3.70 Billion -0.14pp
2009-06-30 0.18% AU$6.93 Million AU$3.78 Billion +0.18pp
2008-06-30 0.00% AU$115.00K AU$4.80 Billion -0.02pp
2007-06-30 0.02% AU$135.00K AU$606.50 Million +0.02pp
2002-06-30 0.00% AU$-6.00K AU$283.35 Million --
pp = percentage points